StreetInsider.com News Articles

Form 6-K Can-Fite BioPharma Ltd. For: Jul 14

Tue, 14 Jul 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260714/26764726.html

Form 6-K Can-Fite BioPharma Ltd. For: Jul 14

Tue, 14 Jul 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260714/26764726.html

Form 6-K Can-Fite BioPharma Ltd. For: Jul 14

Tue, 14 Jul 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260714/26764726.html

Form 6-K Can-Fite BioPharma Ltd. For: Jul 06

Mon, 06 Jul 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260706/26732596.html

Form 6-K Can-Fite BioPharma Ltd. For: Jul 06

Mon, 06 Jul 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260706/26732596.html

Form 6-K Can-Fite BioPharma Ltd. For: Jul 06

Mon, 06 Jul 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260706/26732596.html

Can-Fite BioPharma (CANF) PT Raised to $8 at H.C. Wainwright

Thu, 02 Jul 2026 06:41:54 -0400

(Updated - July 2, 2026 6:41 AM EDT)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Can-Fite BioPharma (NYSE: CANF) to $8.00 (from $5.00) while maintaining a Buy rating.

The analyst commented: "On July 1, 2026, Can-Fite reported that its open-label Phase 2a study evaluating namodenoson, an A3 adenosine receptor (A3AR) agonist, in advanced pancreatic ductal adenocarcinoma (PDAC) achieved its primary safety endpoint — consistent with the broader clinical evidence from other studies with more than 1,600 patients. The study enrolled 20 patients with advanced PDAC who had progressed on standard therapy. Enrolled patients were administered namodenoson as a monotherapy

Can-Fite BioPharma (CANF) PT Raised to $8 at H.C. Wainwright

Thu, 02 Jul 2026 06:41:54 -0400

(Updated - July 2, 2026 6:41 AM EDT)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Can-Fite BioPharma (NYSE: CANF) to $8.00 (from $5.00) while maintaining a Buy rating.

Form 6-K Can-Fite BioPharma Ltd. For: Jul 01

Wed, 01 Jul 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260701/26716708.html

Form 6-K Can-Fite BioPharma Ltd. For: Jul 01

Wed, 01 Jul 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260701/26716708.html

Form 6-K Can-Fite BioPharma Ltd. For: Jul 01

Wed, 01 Jul 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260701/26716708.html

Form 6-K Can-Fite BioPharma Ltd. For: Jun 26

Fri, 26 Jun 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260626/26694943.html

Form 6-K Can-Fite BioPharma Ltd. For: Jun 26

Fri, 26 Jun 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260626/26694943.html

Form 6-K Can-Fite BioPharma Ltd. For: Jun 26

Fri, 26 Jun 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260626/26694943.html

Can-Fite receives Japanese patent allowance for Namodenoson obesity use

Fri, 26 Jun 2026 07:01:04 -0400

Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that the Japan Patent Office has allowed Japanese Patent Application No. 2025-049941, a divisional application covering the use of A3 adenosine receptor agonists, including its drug candidate Namodenoson, for inducing fat loss and treating obesity and related metabolic disorders.

The company states it has previously secured patent protection for this technology in the United States, Canada, Australia, and Israel. The Japanese allowance adds to that portfolio in a market the company describes as one of the world's largest for pharmaceuticals.

Namodenoson is an oral drug candidate that selectively targets the A3 adenosine receptor. The company

Can-Fite receives Japanese patent allowance for Namodenoson obesity use

Fri, 26 Jun 2026 07:01:04 -0400

Namodenoson is an oral drug candidate that selectively targets the A3 adenosine receptor. The company

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology